| PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy A Salmaninejad, SF Valilou, AG Shabgah, S Aslani, M Alimardani, ... Journal of cellular physiology 234 (10), 16824-16837, 2019 | 323 | 2019 |
| Strategies toward rheumatoid arthritis therapy; the old and the new M Abbasi, MJ Mousavi, S Jamalzehi, R Alimohammadi, MH Bezvan, ... Journal of cellular physiology 234 (7), 10018-10031, 2019 | 269 | 2019 |
| PD-1/PD-L and autoimmunity: a growing relationship MR Zamani, S Aslani, A Salmaninejad, MR Javan, N Rezaei Cellular immunology 310, 27-41, 2016 | 247 | 2016 |
| Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients H Valizadeh, S Abdolmohammadi-Vahid, S Danshina, MZ Gencer, ... International immunopharmacology 89, 107088, 2020 | 184 | 2020 |
| The effects of oxygen–ozone therapy on regulatory T‐cell responses in multiple sclerosis patients S Tahmasebi, MT Qasim, MV Krivenkova, AO Zekiy, L Thangavelu, ... Cell biology international 45 (7), 1498-1509, 2021 | 163 | 2021 |
| A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future M Gholamzad, M Ebtekar, MS Ardestani, M Azimi, Z Mahmodi, ... Inflammation Research 68, 25-38, 2019 | 149 | 2019 |
| Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review J Karami, S Aslani, A Jamshidi, M Garshasbi, M Mahmoudi Gene 702, 8-16, 2019 | 148 | 2019 |
| PD-1 and cancer: molecular mechanisms and polymorphisms A Salmaninejad, V Khoramshahi, A Azani, E Soltaninejad, S Aslani, ... Immunogenetics 70, 73-86, 2018 | 126 | 2018 |
| Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients S Tahmasebi, MA El‐Esawi, ZH Mahmoud, A Timoshin, H Valizadeh, ... Journal of cellular physiology 236 (7), 5325-5338, 2021 | 106 | 2021 |
| Epigenetic alterations underlying autoimmune diseases S Aslani, M Mahmoudi, J Karami, AR Jamshidi, Z Malekshahi, ... Autoimmunity 49 (2), 69-83, 2016 | 93 | 2016 |
| Epigenetics in rheumatoid arthritis; fibroblast‐like synoviocytes as an emerging paradigm in the pathogenesis of the disease J Karami, S Aslani, MN Tahmasebi, MJ Mousavi, A Sharafat Vaziri, ... Immunology and cell biology 98 (3), 171-186, 2020 | 74 | 2020 |
| New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis M Mahmoudi, S Aslani, R Fadaei, AR Jamshidi International journal of rheumatic diseases 20 (3), 287-297, 2017 | 73 | 2017 |
| New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications M Mahmoudi, S Aslani, MH Nicknam, J Karami, AR Jamshidi Modern rheumatology 27 (2), 198-209, 2017 | 68 | 2017 |
| The role of magnesium in different inflammatory diseases A Shahi, S Aslani, MR Ataollahi, M Mahmoudi Inflammopharmacology 27, 649-661, 2019 | 65 | 2019 |
| Epigenetic modifications and therapy in multiple sclerosis S Aslani, N Jafari, MR Javan, J Karami, M Ahmadi, M Jafarnejad Neuromolecular medicine 19, 11-23, 2017 | 65 | 2017 |
| Evaluation of DNMT1 gene expression profile and methylation of its promoter region in patients with ankylosing spondylitis S Aslani, M Mahmoudi, M Garshasbi, AR Jamshidi, J Karami, ... Clinical rheumatology 35, 2723-2731, 2016 | 61 | 2016 |
| Role of innate immune system in the pathogenesis of ankylosing spondylitis N Vanaki, S Aslani, A Jamshidi, M Mahmoudi Biomedicine & Pharmacotherapy 105, 130-143, 2018 | 58 | 2018 |
| Atherosclerosis and autoimmunity: a growing relationship M Sanjadi, Z Rezvanie Sichanie, H Totonchi, J Karami, R Rezaei, ... International journal of rheumatic diseases 21 (5), 908-921, 2018 | 58 | 2018 |
| Implications of the noncoding RNAs in rheumatoid arthritis pathogenesis MJ Mousavi, A Jamshidi, A Chopra, S Aslani, M Akhlaghi, M Mahmoudi Journal of cellular physiology 234 (1), 335-347, 2019 | 57 | 2019 |
| Epigenetics in osteoarthritis: novel spotlight A Fathollahi, S Aslani, A Jamshidi, M Mahmoudi Journal of cellular physiology 234 (8), 12309-12324, 2019 | 51 | 2019 |
